{"id":3708,"date":"2024-06-12T09:14:46","date_gmt":"2024-06-12T07:14:46","guid":{"rendered":"https:\/\/mikrobiomik.net\/?p=3708"},"modified":"2024-09-05T10:38:46","modified_gmt":"2024-09-05T08:38:46","slug":"asebio-2023-report-milestones-and-challenges-for-spanish-biotech","status":"publish","type":"post","link":"https:\/\/mikrobiomik.net\/en\/asebio-2023-report-milestones-and-challenges-for-spanish-biotech\/","title":{"rendered":"AseBio 2023 Report: Milestones and challenges for Spanish Biotech"},"content":{"rendered":"[vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/1″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”]\"Asebio<\/p>\n

12\/06\/2024<\/strong><\/p>\n

AseBio \u2013 (Spanish Asociation of biotech companies) presented the AseBio 2023 Report “25 years of biotechnology” <\/strong>on 12 June in Madrid.
\nDr. Juan Basterra was invited, by the organization, to take part of the debate at the main scenario, join Cristina Nadal, executive director of Policy Government-Corporate Affairs from MSD to talk about regulatory issues. As Mikrobiomik is leading the path developing medicines based on human microbiome, there is no background in Europe, MBK-01 will set a precedent in the field of microbiota.
\nThis report is extremely important for the Spanish biotech sector, as it allows us to assess the context in which we operate, its current situation and its evolution, as it is a global reference for its quality sources.
\nWe would like to highlight the following data:<\/p>\n